Global Needle Free Injector Market to 2026 Primarily Driven by Increasing Prevalence of Chronic Disease – ResearchAndMarkets.com – Press Release

The “Global Needle Free Injector Market- Strategies and Market Share and Industry Forecast to 2026” report has been added to ResearchAndMarkets.com’s offering.

The global needle-free injectors market is primarily driven by the increasing prevalence of chronic diseases and technological advancements.

In addition, demand for innovative and effective drug delivery platforms, owing to an increase in the prevalence of chronic diseases and rise of point-of-care are major factors triggering growth for the needle-free injectors market.

However, there are certain challenges such as the availability of alternative drug delivery platforms. For instance, in 2017, FDA approved the first digital pill that is sensor embedded and leads to track the ingestion of medications inside the body.

Moreover, in 2018, Rani Therapeutics (US) secured funding of $53 million from various investors that include GeneScience Pharmaceuticals (China) and Shire (Europe) for manufacturing robotic pills for clinical trials. The robotic pill developed by the company can inject drugs directly into the small intestine. This can emerge as a safe and pain-free alternative technology for the delivery of injectable drugs.

Thus, technological advancements and the new product launch in the needle-free injectors market is expected to drive market growth over the forecast period.

The global needle-free injectors market has been segmented based on application, site of delivery, end-user, type of medication, usability, product and technology. The technology segment is sub-segmented into jet injectors, spring, laser, vibration-based needle-free injectors.

Jet injectors is the leading segment in terms of revenue in the global needle-free injectors market with around 42% market share. The dominance of the jet injectors segment is primarily attributed to the introduction of novel jet injectors due to the rise in the prevalence of chronic diseases.

According to World Economic Forum (2017), 1 in 3 adults across the world has multiple chronic conditions such as diabetes, cardiovascular disease, cancer, depression etc. The high prevalence of these diseases is creating a demand for novel needle-free injectors. Moreover, spring-based needle free injector segment is anticipated to grow at the highest CAGR of around 15.2% during the forecast period. The fastest growth rate of the transdermal patch segment is contributed to by the emergence of novel technology.

Geographically, the needle-free injectors market has been segmented into North America, Europe, Asia Pacific, and Rest of World (ROW). Asia Pacific is expected to grow at the highest CAGR of 15.3%. Asia Pacific needle-free injectors market growth is because of the rising prevalence of chronic diseases in countries such as China, India, etc. along with government support for the development of advanced drug delivery technologies. China holds the largest market share of around 34% in 2019 in Asia Pacific needle-free injectors market. High R&D investment by companies in the drug delivery technologies sector in China is boosting growth in needle-free injectors market owing to the high prevalence of cancer in the region.

Key Topics Covered:

1. Acknowledgment

2. Summary

3. Industry Outlook

4. Market Share Analysis

5. Regulatory Landscape: Needle Free Injector

6. Analysing Needle Free Injector

7. Analysing Needle Free Injector Cross Borders

8. Competitive Landscape

9. Patent Analysis

10. Company Profiling

Companies Mentioned

• Activa Brand Products, Inc
• Antares Pharma, Inc.
• Bioject Medical Technologies Inc.
• Crossject SA
• Endo International plc
• European Pharma Group
• INJEX Pharma AG
• Medical International Technology, Inc.
• National Medical Products Inc.
• PenJet Corporation
• PharmaJet
• Valeritas, Inc.

For more information about this report visit https://www.researchandmarkets.com/r/602l04

View source version on businesswire.com: https://www.businesswire.com/news/home/20210827005109/en/